Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) ('Amylyx' or the 'Company') today announced the presentation of new exploratory analyses from the Phase 2 PREVENT and Phase 2b clinical trials of avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist for the treatment of post-bariatric hypoglycemia (PBH) at the Endocrine Society's annual meeting (ENDO 2025).
In the Phase 2b trial, avexitide 90 mg once daily, the dose being evaluated in the pivotal Phase 3 LUCIDITY trial, led to a 64% least-squares (LS) mean reduction (p=0.0031) vs. baseline in the composite rate of Level 2 and Level 3 hypoglycemic events in PBH, with more than half of the participants experiencing no events during the treatment period. LUCIDITY is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in approximately 75 participants with PBH following Roux-en-Y gastric bypass surgery. The FDA-agreed-upon primary endpoint of LUCIDITY is reduction in the composite of Level 2 and Level 3 hypoglycemic events. Consistent reductions in composite rate of Level 2 and Level 3 hypoglycemic events also were seen with avexitide 45 mg twice daily studied in the Phase 2b trial and avexitide 30 mg twice daily and 60 mg once daily studied in the Phase 2 PREVENT trial. New pharmacokinetic (PK) and pharmacodynamic (PD) data were also presented demonstrating continuous pharmacologic activity of the 90 mg once daily dose regimen for a 24-hour period.
'Post-bariatric hypoglycemia can profoundly disrupt daily life, requiring individuals to carefully manage meals, social interactions, and routines, often while living in fear of their next hypoglycemic event. The new analysis presented at ENDO 2025 continues to support that avexitide may significantly reduce the frequency of these events,' said Marilyn Tan, MD, FACE, Principal Investigator of the LUCIDITY trial and Clinical Associate Professor at Stanford University.
Camille L. Bedrosian, MD, Chief Medical Officer of Amylyx, added, 'Post-bariatric hypoglycemia is a serious and underrecognized condition with no FDA-approved treatments. The data presented show that, in an exploratory analysis from the Phase 2 PREVENT and Phase 2b clinical trials, avexitide significantly reduced the composite rate of Level 2 and 3 hypoglycemic events, including at the 90 mg once daily dose that is being studied in our pivotal Phase 3 LUCIDITY trial. We are particularly encouraged that over half of participants did not experience Level 2 or Level 3 hypoglycemic events during the treatment period. In addition, the pharmacokinetic and pharmacodynamic data demonstrated continuous pharmacologic activity of avexitide 90 mg once daily dose over 24 hours. We continue to be encouraged by avexitide's potential to deliver consistent, meaningful benefit to people living with PBH.'
The population PK and PD analyses presented at ENDO 2025 demonstrated that avexitide 90 mg once daily maintained consistent GLP-1 receptor inhibition from morning to midnight and between doses. In vitro potency studies showed an IC₅₀ of approximately 20-30 nM (70-100 ng/mL), indicating robust target inhibition even in the presence of significant levels of GLP-1. PK modeling demonstrated that avexitide plasma levels exceeded IC₅₀ for a full 24-hour period.
LUCIDITY was informed by data from five PBH clinical trials of avexitide showing consistent, dose-dependent effects, including statistically significant and clinically meaningful reductions in hypoglycemic events. Avexitide was generally well-tolerated, with a favorable safety profile replicated across clinical trials. Completion of recruitment for LUCIDITY is expected in 2025, with a data readout anticipated in the first half of 2026 and, if approved, commercial launch anticipated in 2027.
The presentation and posters are available on the ' Presentations ' tab of the Amylyx website.
Webcast Information
Amylyx will host an investor event today, July 13, 2025, at 6:00 p.m. PT / 9:00 p.m. ET in San Francisco to discuss post-bariatric hypoglycemia and avexitide. A live webcast of the presentation and Q&A portion of the event can be accessed under 'Events and Presentations' in the Investor section of the Company's website, https://investors.amylyx.com/events-presentations. The webcast will be archived and available for replay for 90 days following the event.
About Avexitide
Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five Phase 1 and Phase 2 clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI). The U.S. Food and Drug Administration (FDA) has granted avexitide Breakthrough Therapy Designation for both indications, Rare Pediatric Disease Designation in congenital HI, and Orphan Drug Designation for the treatment of hyperinsulinemic hypoglycemia (which includes PBH and congenital HI). Avexitide is designed to bind to the GLP-1 receptor on pancreatic islet beta cells and inhibit the effect of GLP-1 to mitigate hypoglycemia by decreasing insulin secretion and stabilizing blood glucose levels. In PBH, excessive GLP-1 can lead to the hypersecretion of insulin and subsequent debilitating hypoglycemic events. In two Phase 2 PBH clinical trials, avexitide demonstrated highly statistically significant reductions in hypoglycemic events. These events can lead to autonomic and neuroglycopenic symptoms that can have a devastating impact on daily living.
About Post-Bariatric Hypoglycemia (PBH)
Post-bariatric hypoglycemia (PBH) is a condition that is estimated to affect approximately 8% of people in the U.S. who have undergone the two most common types of bariatric surgery, sleeve gastrectomy and Roux-en-Y gastric bypass (approximately 160,000 people in the U.S.). PBH is thought to be caused by an excessive glucagon-like peptide-1 (GLP-1) response leading to hypoglycemia and impaired quality of life. PBH can cause debilitating hypoglycemic events associated with inadequate supply of glucose to the brain, known as neuroglycopenia. Clinical manifestations can include impaired cognition, loss of consciousness, and seizures. PBH is also associated with a high degree of disability that can result in major disruptions to independent living. There are no approved therapies for PBH.
About the LUCIDITY Trial
LUCIDITY ( NCT06747468 ) is an approximately 75-participant, multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of avexitide in participants with PBH following Roux-en-Y gastric bypass (RYGB) surgery. The Phase 3 trial will be conducted at approximately 20 sites in the U.S. Participants will be randomized 3:2 to receive either 90 mg of avexitide subcutaneously once daily or placebo. The trial includes an up to six-week screening period, including a three-week run-in period, and a 16-week double-blind treatment period. Participants who complete the double-blind period will be eligible to enter an open-label extension (OLE) period with a duration of 32 weeks. The primary efficacy objective of LUCIDITY will evaluate the FDA-agreed upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16. Safety and tolerability will also be evaluated.
About Amylyx Pharmaceuticals
At Amylyx, our mission is to usher in a new era of treating diseases with high unmet needs. Where others see challenges, we see opportunities that we pursue with urgency, rigorous science, and unwavering commitment to the communities we serve. We are currently focused on three investigational therapies across several neurodegenerative and endocrine diseases in which we believe they can make the greatest impact. For more information, visit amylyx.com and follow us on LinkedIn and X. For investors, please visit investors.amylyx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, Amylyx' expectations regarding: the potential of avexitide as a treatment for PBH; expectations regarding the timing for recruitment completion and topline data readout of the Phase 3 LUCIDITY trial of avexitide in PBH; and expectations regarding timing for potential commercialization of avexitide. Any forward-looking statements in this press release and related comments in the Company's earnings conference call are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of Amylyx' program development activities; Amylyx' ability to execute on its regulatory development plans and expectations regarding the timing of results from its planned data announcements and initiation of clinical studies; the risk that early-stage results may not reflect later-stage results; Amylyx' ability to fund operations, and the impact that global macroeconomic uncertainty, geopolitical instability, and public health events will have on Amylyx' operations, as well as the risks and uncertainties set forth in Amylyx' United States Securities and Exchange Commission (SEC) filings, including Amylyx' Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the SEC. All forward-looking statements contained in this press release and related comments in our earnings conference call speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250713408050/en/
CONTACT: Media
Amylyx Media Team
(857) 320-6191
[email protected]
Lindsey Allen
(857) 320-6244
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH CLINICAL TRIALS RESEARCH PHARMACEUTICAL SCIENCE BIOTECHNOLOGY
SOURCE: Amylyx Pharmaceuticals, Inc.
Copyright Business Wire 2025.
PUB: 07/13/2025 05:00 PM/DISC: 07/13/2025 05:00 PM
http://www.businesswire.com/news/home/20250713408050/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Couple with spina bifida finds family despite adoption barriers
Kelly and Larry Peterson's love story began at a summer camp for children with spina bifida. Born on the same day, the couple discovered they had much in common beyond their shared birthday and disability. Spina bifida is a condition where the spinal column and casing around the spinal cord don't form completely, affecting motor ability and the ability to walk. Before 1960, the survival rate for babies with spina bifida was about 10%. Even as medical science improved, some still viewed the diagnosis as a death sentence. Both Kelly and Larry went on to live happy childhoods and, in high school, the pair started dating. Today, they reminisce about the days when they had to pay for phone minutes and their parents would warn them to watch their phone usage. "We always, we just kind of got along really easily," Larry Peterson said. The couple married in 2015 and, within six months, began discussing adoption. However, they quickly encountered barriers that highlighted ongoing discrimination against people with disabilities. "We actually came across an agency who flat out said, 'No, we have a list of disabilities that we don't work with potential adoptive parents, if they have X, Y, and Z conditions and spina bifida is on that list,'" Kelly Peterson said. This month marks the 35th anniversary of the Americans with Disabilities Act, which prohibits discrimination against Americans with disabilities. The law requires businesses like restaurants, hotels and grocery stores to provide people with disabilities equal opportunities to access goods and services. But in practice, when it comes to services like adoption, equal access is not always guaranteed. The rejection was disheartening, but the Petersons understood the agencies' concerns about liability and whether adoptive families could handle the challenges ahead. Eventually, one organization agreed to help, changing everything for the family. While browsing the agency's website, Kelly spotted a little girl with spina bifida. "As I'm on the website, I see a little girl with spina bifida and I was like, 'how do we miss this?!'" the couple said in unison. That little girl was Hadley, who became the Petersons' daughter in December 2018. "It was love at first sight," Larry Peterson said. Like many children with spina bifida, Hadley also has other conditions, including autism and a speech disorder. The Petersons regularly bring Hadley to therapy and the library to help her build independence. The couple believes their shared experience with spina bifida makes them uniquely suited to care for Hadley's complex needs. "We've been through it. I mean, we've been through pretty much everything you could go through with the disability we have," Larry Peterson said. "I remember being a kid and thinking when adults would tell me, 'This is good for you,' how do you know you haven't been through it? With her, we'll be able to say we've been there," Kelly Peterson said. Jennifer Kelly, an adoption specialist who works with children with severe medical needs and helps prospective parents with disabilities adopt, matched the Peterson family. She emphasizes that adults with disabilities shouldn't be automatically discounted as adoptive parents. "Adults with disabilities, they have considered those challenges," Jennifer Kelly said. "Maybe they have a couple of weak spots, but we can put some resources in place that can help with that." The Petersons were thoughtful about their limitations, acknowledging there were some children they felt they couldn't adequately care for. Their house is already modified specifically for Hadley's needs. One of the family's biggest concerns was cost. Kelly is a teacher and Larry works at a call center, and medical bills can be expensive. Jennifer Kelly didn't just match the family with Hadley; she also helped them secure federal benefits available to families raising children with severe medical needs. Shriners Hospitals for Children have also alleviated the financial burden on the Petersons by covering the costs of Hadley's medical procedures, some of which would normally cost tens of thousands of dollars. The family now worries about how potential cuts to Medicaid will impact their ability to provide Hadley with what she needs in the future. "She is my world. I can't imagine her not being here," Larry Peterson said. "We couldn't be happier to have this opportunity," Kelly Peterson added. When asked if they might become grandparents one day, both Larry and Kelly responded in unison: "Anything is possible!" Sen. Lindsey Graham says "a turning point, regarding Russia's invasion of Ukraine, is coming" Student's unique talent that's for the birds Candy Land, the game that still hits a sweet spot
CBS News
28 minutes ago
- CBS News
FDA approves new blue food dye derived from gardenia fruit
The U.S. Food and Drug Administration on Monday approved a new blue color additive derived from the fruit of the gardenia, a flowering evergreen. The color is approved for use in sports drinks, flavored or enhanced non-carbonated water, fruit drinks, ready-to-drink teas as well as hard and soft candy. Petitioned by the Gardenia Blue Interest Group, the additive is made by refining the compound genipin — derived from crushed Gardenia jasminoides Ellis fruit, which is often used in traditional Chinese medicine — by reacting it with soy protein hydrolysate. Though soy, a potential allergen, is used to make gardenia blue, the group has asked the FDA to exempt it from having to declare it as such. In its request, it says the soy protein is not expected to be detected in the final color additive and therefore will not cause allergic reactions. The FDA says it is still reviewing the request. "Every day, children are exposed to synthetic chemicals in food that serve no purpose and threaten their health," Health Secretary Robert F. Kennedy Jr. said in a news release. "The FDA's approval of gardenia blue shows we're finally putting kids first. Thanks to Dr. Marty Makary's bold leadership, we're cutting through industry influence and taking decisive action to Make America Healthy Again." The FDA says this marks the fourth color derived from natural sources approved by the administration for use in foods in the last two months. In May, three other colors were approved, including galdieria extract blue, calcium phosphate (white) and butterfly pea flower extract (blues, purples and greens). Kennedy previously called on companies to phase out all petroleum-based dyes by the end of next year, with the goal to replace them with natural alternatives in the U.S. food supply. The food dye industry has denied any safety concerns with artificial dyes. The International Association of Color Manufacturers said in a statement after Kennedy's initial announcement that artificial dyes are "essential for consistency, visual appeal, and consumer trust in food products."
Yahoo
32 minutes ago
- Yahoo
Beyond melatonin: How doctors and sleep experts really recommend you overcome jet lag
Whether you're flying across the country or across the globe, that mind-melting, time-warping experience can leave even the most seasoned traveler wrestling with a serious case of jet lag. An honest-to-goodness (albeit temporary) sleeping disorder, jet lag strikes when your body's internal 24-hour clock (aka your circadian rhythm) gets completely out of sync with your new time zone. The result? You feel like you've sprinted directly into a wall of bone-deep fatigue and exhaustion. "Jet lag usually occurs when you travel across more than two time zones," says Dr. Joyce Adesina, a sleep medicine specialist with Keck Medicine of USC in Los Angeles. "So you're either experiencing some sort of insomnia or excessive daytime sleepiness because of this trip." But that's not all — other symptoms can include feeling disoriented, changes in appetite, digestive issues or shifts in your menstrual cycle. Headaches and irritability are also common. Even the idea of jet lag is enough to keep some would-be vacationers home: A 2024 survey discovered that one in five U.S. travelers would actually bow out of a trip if they thought jet lag was going to get the best of them. But there's no need to panic: There are plenty of expert-backed, scientifically-valid jet lag remedies to help nearly every traveler. Here's what you need to know — and how to get over jet lag. You know how you often feel tired, headachy and even a little disorientated during or immediately after a long flight? That's not jet lag; it's something called travel fatigue, and it strikes thanks to a combo of icks like low humidity, dehydration, low air pressure and sleep loss. Jet lag, on the other hand, occurs in the next few days after your flight. The symptoms are similar and often go hand in hand, so many people refer to the entire post-flight travel experience as jet lag. The severity of your jet lag is affected by several factors. Age: While everyone is susceptible to jet lag, research shows that people over the age of 60 experience circadian changes that can make it more difficult to recover from jet lag. Number of time zones: Generally, the more time zones you travel across, the longer it'll take to recover. There's actually a rough formula: Expect about one day of recovery for each time zone you cross. "If you are going from the West Coast to the East Coast of the United States, then it'll take about three days to adjust, since there is a three-hour difference. If you are going across seven time zones, it will take a week," says Bryce Mander, PhD, an associate professor of psychiatry and human behavior at the University of California, Irvine, School of jet lag affects everyone differently. "There are some people who travel one time zone, and that really bothers them. It really is very disruptive to their entire routine, to their sleep, to when they feel good. And there are other people who can travel for four or five hours, and it's not a big deal for them," says Jamie Zeitzer, PhD, co-director of the Stanford Center for Sleep and Circadian Sciences. Destination: Your body's natural clock actually runs slightly longer than 24 hours, which means it's easier to stretch your day out than to compress it. That's why traveling west (where you "gain" time) feels more natural than traveling east (where you "lose" time), according to research. Sleep before travel: If your sleep is not great in the days leading up your flight, you're at a higher risk of getting jet lag after traveling. First, the bad news: You can't eliminate jet lag completely. However, that doesn't mean you're destined for fatigue-fueled travel. "There are essentially two cues that can help you swing your circadian rhythm and soften the effects of jet lag," says Dr. Sam Kashani, an assistant clinical professor of sleep medicine at David Geffen School of Medicine at UCLA. "One is bright light exposure, and the other is strategically timed melatonin." The timing of each is key to your jet lag recovery. Light is your secret weapon for beating jet lag because it directly controls your circadian rhythm. Here's how it works: Light exposure suppresses melatonin, the hormone your body naturally releases about one to three hours before bedtime. By strategically timing when you get light, you can actually shift your internal clock. The key is matching your light exposure to your travel direction. The exact timing will depend on how many time zones you're crossing and your desired sleep schedule at your destination, but here's the gist, according to Kashani: Evening light usually helps you adapt to a later time zone after traveling west, whereas first-thing morning light can help you adjust to an earlier time zone after traveling east. If it's not sunny or bright outside when you're trying to make these adjustments? Adesina recommends considering a light box for boosting exposure ... or sunglasses when you need to avoid light. Light directly affects the melatonin your body releases — and since melatonin is what signals sleepiness, taking melatonin supplements at strategic times may also help shift your internal clock. "For jet lag, you must take melatonin across multiple days at low doses —1 to 3 milligrams or less — at least three hours before [your desired] bedtime, and after you take it, you need to stay awake until your desired bedtime," says Mander. (Some experts even suggest taking melatonin a few days before your trip.) That said, melatonin is not a sleeping pill. Instead, melatonin can improve certain symptoms of jet lag, like alertness, and reduce daytime sleepiness, but it might not help shorten the time it takes for jet-laggers to fall asleep. Remember, if you're considering taking any supplements or medication to help with your jet lag, consult your doctor first. (Learn which melatonin supplement might be right for you.) The easiest way to figure out your light exposure and melatonin timing is to use a jet lag calculator, such as the one on says Kashani. Use the tool to start shifting your schedule before, after or during your flight. The calculator considers factors including your departure and arrival locations, flight times and your typical sleep and wake schedule. You can also choose whether to incorporate melatonin into your adjustment plan. There's also an option to include melatonin as part of your adjustment plan. Another option is the Timeshifter app, favored by Mander, that formulates a personalized jet-lag recovery plan, that includes advice on when to abstain from caffeine and when to sneak in a cat nap. There are other ways you can get over jet lag. You can get a jump start on adjusting your circadian rhythm by gradually shifting your sleep schedule at home a few days before your flight. Traveling east? Hit the sack 30 minutes earlier each night until you're one to two hours ahead. If you're traveling west, do the opposite — go to bed 30 minutes later. "Since it takes a number of days to adjust to a new time zone based on how many time zones you cross, if you're going on a short trip, try to stay on your home time zone [schedule] to minimize jet lag," says Mander. The reason? Shifting to a new time zone on a brief getaway means you'll be more jet lagged coming home than you would have been had you stayed on your home time zone. No matter how much you want to devour that in-flight meal, think about what time it is where you're heading before you do, says Rebecca Robbins, PhD, an assistant professor of medicine at Harvard Medical School and sleep scientist at Brigham and Women's Hospital in Boston. "This will help you make good decisions while you're traveling, like maybe forgoing a meal that's being served on the plane and getting something at the airport instead." Keep that mentality when on the ground too. "It's always best to eat on the schedule of your destination," says Adesina. That means don't eat lunch at breakfast time or vice versa. All those cues help you reset your internal clock." Beyond food, be careful with caffeine. Adesina recommends avoiding caffeine after midday in the time zone of your new destination. And since both caffeine and alcohol can disrupt sleep, consider sticking to water on long flights. One key for mitigating jet lag is to arrive at your destination as rested and relaxed as possible, which can be tricky with air travel. That's why Robbins suggests bringing familiar comfort items from home on your flight — things like a cozy shawl, a trusted eye mask or earplugs you've already tested at home, noise-canceling headphones and a high-quality travel pillow. These small touches can make a real difference in your travel experience. Research supports this approach: A small study of competitive cricket players found that better sleep quality during flights (with fewer disruptions) helped with jet lag recovery. If you can swing it, consider booking a seat with more leg room. (Those cricket players snoozed well in business class.) Zeitzer, who once flew business class to Korea, agrees: "I have to say, jet lag is a lot less bad when you're flying business class. You have all this physical space. You have mental space. You're eating better. You're more relaxed." The only downside? "Now that I know how good the other half has it, when I have to fly economy to Korea, the jet lag is worse!" While not worrying about jet lag is easier said than done, mindset can make a difference. "The more you worry about it, the worse that it's going to be," says Zeitzer. He says to look for ways to reduce that anxiety to make it easier for you to travel. Plan your strategy: Use Sleepopolis jet lag calculator or the Timeshifter app to determine when to get light and/or how much melatonin to take before, during and after your flight. Start shifting early: Try adjusting your wake time and bedtime in the days prior to your travel. The jet lag calculator or app can help. Get your melatonin: Talk to your health care provider about possibly taking a low-dose melatonin supplement, like Thorne Melaton-3, our pick for the best overall melatonin supplement. Pack comfort items: Stash items in your carry-on bag that help you feel relaxed such as a travel pillow, earplug or eye mask. Consider Travelrest's Nest Ultimate Memory Foam Travel Pillow, Loop Quiet 2 earplugs and the Nidra Deep Rest Eye Mask. Watch what you consume: Try to avoid alcohol and caffeine, which can mess up sleep. And drink plenty of water to stay hydrated. Eat strategically: Start eating on your new schedule as soon as possible, which means you'll need to be mindful of the time airplane meals are served. And when you are eating during travel, have light meals to help avoid digestive issues. Stay comfortable: Make sure to stretch, move about the cabin and engage in relaxing activities on board, says Mander. Use your comfort items to help you relax. Get the right light: Again, turn to your jet lag calculator or app to determine the best times to get light. Use a light box or wear sunglasses if needed. (Try Ray-Ban Wayfarers or Quay After Hours sunglasses.) Settle in smart: Take a shower once you arrive and a quick 20-minute nap if needed — only if it's at least eight or more hours before your planned bedtime. Eat and drink on schedule: Have meals according to the new time zone. Get plenty of water to stay hydrated. Take melatonin, if planned: Follow your calculator or app guidance for timing — and your health care provider's advice. Exercise outdoors: The fresh air and natural light exposure can help adjust your internal clock, Robbins suggests. Keep it simple for short trips: If your trip is brief, consider staying on your home time zone schedule. Stay positive: Worrying about jet lag doesn't help. Try to relax and enjoy your trip! Joyce Adesina, MD, sleep medicine specialist with Keck Medicine of USC Sam A. Kashani, MD, assistant clinical professor of sleep medicine at David Geffen School of Medicine at UCLA Bryce Mander, PhD, associate professor of psychiatry and human behavior at the University of California, Irvine, School of Medicine Rebecca Robbins, PhD, assistant professor of medicine at Harvard Medical School and sleep scientist at Brigham and Women's Hospital in Boston Jamie Zeitzer, MD, co–director of the Stanford Center for Sleep and Circadian Sciences and professor of psychiatry and behavioral sciences sleep medicine at Stanford University Our health content is for informational purposes only and is not intended as professional medical advice. Consult a medical professional on questions about your health.
